Reviva Pharmaceuticals Presents New Vocal Biomarker Data From Phase 3 RECOVER Trial For Brilaroxazine In Schizophrenia; Statistically Significant Speech Latency Results Highlight Efficacy For Negative Symptoms; Additional Data From Open Label Extension Study Expected Q4 2024
Portfolio Pulse from Benzinga Newsdesk
Reviva Pharmaceuticals has presented new data from its Phase 3 RECOVER trial for Brilaroxazine, showing statistically significant results in speech latency, indicating efficacy in treating negative symptoms of schizophrenia. Further data from an open-label extension study is expected in Q4 2024.
September 09, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Reviva Pharmaceuticals' Phase 3 trial for Brilaroxazine shows significant efficacy in treating negative symptoms of schizophrenia, with promising speech latency results. Further data is anticipated in Q4 2024.
The statistically significant results in speech latency from the Phase 3 trial suggest Brilaroxazine's potential efficacy in treating schizophrenia, which could positively impact Reviva Pharmaceuticals' stock. The anticipation of additional data in Q4 2024 adds to the potential for future positive developments.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100